Acuta Capital Partners’s Outlook Therapeutics OTLK Stock Holding History

Acuta Capital Partners’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-182	Closed	-$15K	–	34
2018 Q4	$15K	Hold	182	–	–	0.01%	21
2018 Q3	$29K	Hold	182	–	–	0.01%	31
2018 Q2	$25K	Hold	182	–	–	﹤0.01%	59
2018 Q1	$26K	Hold	182	–	–	﹤0.01%	59
2017 Q4	$38K	Hold	182	–	–	0.01%	72
2017 Q3	$40K	Hold	182	–	–	0.01%	62
2017 Q2	$29K	Hold	182	–	–	0.01%	58
2017 Q1	$78K	Hold	182	–	–	0.02%	65
2016 Q4	$88K	Sell	182 -1,352	-88%	-$757K	0.03%	44
2016 Q3	$1.04M	Buy	1,534 +13	+0.9%	+$8.26K	0.39%	45
2016 Q2	$828K	Buy	+1,521	New	+$907K	0.4%	47

Other funds holding OTLK

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PWMG

Prestige Wealth Management Group Flemington, New Jersey $509M AUM 15.69% 1-Year Est. Return

RIA

Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return

Acuta Capital Partners's OTLK Position: Q1 2019 in Review

Acuta Capital Partners sold out of Outlook Therapeutics (OTLK) in Q1 2019, closing a stake of 182 shares — an estimated $15K sold.

Acuta Capital Partners first reported a position in OTLK in Q2 2016 and held it in 11 quarters. The position peaked at $1.04M in Q3 2016. 14 funds tracked by Wall St. Rank hold OTLK as of Q1 2019.

Acuta Capital Partners reported no remaining Outlook Therapeutics position as of Q1 2019 after selling out during the quarter.
Acuta Capital Partners sold 182 Outlook Therapeutics shares in Q1 2019, an estimated $15K.
Acuta Capital Partners first reported a position in Outlook Therapeutics in Q2 2016 and held it in 11 quarters.
Acuta Capital Partners's Outlook Therapeutics position peaked at $1.04M in Q3 2016.
14 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2019.

Based on Acuta Capital Partners's 13F filing for Q1 2019, filed 14 May 2019.